| The molecular taxonomy of primary prostate cancer A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ... Cell 163 (4), 1011-1025, 2015 | 2786 | 2015 |
| The evolutionary history of lethal metastatic prostate cancer G Gundem, P Van Loo, B Kremeyer, LB Alexandrov, JMC Tubio, ... Nature 520 (7547), 353-357, 2015 | 1504 | 2015 |
| Critical assessment of automated flow cytometry data analysis techniques N Aghaeepour, G Finak, FlowCAP Consortium, Dream Consortium, ... Nature methods 10 (3), 228-238, 2013 | 685 | 2013 |
| Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis H Cheng, L Zhang, DE Cogdell, H Zheng, AJ Schetter, M Nykter, ... PloS one 6 (3), e17745, 2011 | 565 | 2011 |
| Driver fusions and their implications in the development and treatment of human cancers Q Gao, WW Liang, SM Foltz, G Mutharasu, RG Jayasinghe, S Cao, ... Cell reports 23 (1), 227-238. e3, 2018 | 548 | 2018 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 504 | 2018 |
| Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer D Yang, Y Sun, L Hu, H Zheng, P Ji, CV Pecot, Y Zhao, S Reynolds, ... Cancer cell 23 (2), 186-199, 2013 | 452 | 2013 |
| Evaluation of methods for modeling transcription factor sequence specificity MT Weirauch, A Cote, R Norel, M Annala, Y Zhao, TR Riley, ... Nature biotechnology 31 (2), 126-134, 2013 | 420 | 2013 |
| Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ... JNCI: Journal of the National Cancer Institute 109 (12), djx118, 2017 | 411 | 2017 |
| Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ... JAMA oncology 2 (12), 1598-1606, 2016 | 381 | 2016 |
| Function of C/EBPδ in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals V Litvak, SA Ramsey, AG Rust, DE Zak, KA Kennedy, AE Lampano, ... Nature immunology 10 (4), 437-443, 2009 | 337 | 2009 |
| Gene expression dynamics in the macrophage exhibit criticality M Nykter, ND Price, M Aldana, SA Ramsey, SA Kauffman, LE Hood, ... Proceedings of the National Academy of Sciences 105 (6), 1897-1900, 2008 | 278 | 2008 |
| The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma BC Parker, MJ Annala, DE Cogdell, KJ Granberg, Y Sun, P Ji, X Li, ... The Journal of clinical investigation 123 (2), 2013 | 268 | 2013 |
| A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding Q Huang, T Whitington, P Gao, JF Lindberg, Y Yang, J Sun, MR Väisänen, ... Nature genetics 46 (2), 126-135, 2014 | 234 | 2014 |
| Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ... European urology 72 (1), 34-42, 2017 | 232 | 2017 |
| Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ... European urology 75 (4), 667-675, 2019 | 189 | 2019 |
| Immunogenomic landscape of hematological malignancies O Dufva, P Pölönen, O Brück, MAI Keränen, J Klievink, J Mehtonen, ... Cancer Cell 38 (3), 380-399. e13, 2020 | 175 | 2020 |
| Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ... Clinical cancer research 23 (21), 6487-6497, 2017 | 166 | 2017 |
| Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer KA Leinonen, OR Saramäki, B Furusato, T Kimura, H Takahashi, S Egawa, ... Cancer epidemiology, biomarkers & prevention 22 (12), 2333-2344, 2013 | 164 | 2013 |
| Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression L Latonen, E Afyounian, A Jylhä, J Nättinen, U Aapola, M Annala, ... Nature communications 9 (1), 1176, 2018 | 156 | 2018 |
Matti AnnalaResearcher, Tampere UniversityVerified email at tuni.fi
